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 Introduction 
 Multidisciplinary team (MDT) working is central to the mod-
ern management of cancer patients. MDTs were introduced 
to help overcome the shortfalls of cancer care in the United 
Kingdom and were important parts of both the Calman – Hine 
report 1 and the NHS Cancer Plan produced in 2000. 2 Th e role 
of MDTs was three-fold: 
 1.  To ensure that all aspects of diagnosis, treatment and 
care are provided by designated specialists, working 
together eff ectively in multidisciplinary teams; 
 2.  To ensure that care is given according to recognised 
guidelines; 
 3.  To ensure that mechanisms are in place to support entry 
of eligible patients into clinical trials. 3 
 Th e publication of the  ‘ Improving Outcomes Guidance 
by the National Institute for Health and Clinical Excellence 
(NICE) ’ for the diff erent cancer sites has been the major 
driver in ensuring MDT working. 4 Th e guidance for CNS 
tumours was published in 2006, and it outlines the impor-
tance of discussing all patients pre-operatively in a MDT set-
ting to ensure the best surgical treatment for these tumours. 
Th e MDT is also meant to ensure treatment accords to recog-
nised guidelines  – including implementing NICE guidance. 
Th ere has been little published on the eff ectiveness of MDTs 4 ; 
there are even fewer studies looking at the implementation 
of NICE guidance by MDTs. 
 High grade gliomas are the commonest intrinsic brain 
tumours and account for more average years of life lost than all 
the commoner cancers. 5 It has become the commonest cause 
of cancer death in men under the age of 45 and women under 
the age of 35. Although surgical resection can greatly reduce 
tumour bulk, complete excision is virtually impossible due to 
the infi ltrative nature of these tumours. Although adjuvant 
radiotherapy and chemotherapy improves survival, death is 
inevitably from either recurrent or progressive disease. 
 In an attempt to treat the infi ltrating tumour cells, there 
has been much interest in using local therapies inserted 
at the time of surgery. Carmustine wafers (Gliadel  Ò  ) are 
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 Abstract 
 Background. Multidisciplinary team (MDT) working in oncology 
aims to improve outcomes for patients with cancer. One role 
is to ensure the implementation of best practice and National 
Institute for Health and Clinical Excellence (NICE) guidance. In 
this study, we have assessed the role of MDT in implementing 
the TA121 appraisal of the use of carmustine wafers in high 
grade gliomas.  Methods. 296 patients with high-grade 
glioma suitable for maximal resection were recruited from 17 
Neurosurgical Centres. The number of patients treated with 
carmustine wafers and reasons for not using this were recorded. 
Complications at 48 hours post-operatively and at 6 weeks 
post-radiotherapy were recorded.  Results. 94/296 (32%) of 
suitable patients received carmustine wafers. In 55% of cases 
carmustine was not used due to either surgeon preference or a 
lack of an MDT decision. There was no increased complication 
rate with carmustine use at either 48 hours post-surgery or at 
6 weeks post radiotherapy. Use of carmustine wafers did not 
decrease access to and use of chemoradiotherapy.  Conclusions. 
One third of patients suitable for carmustine wafers received 
them. Their use was neither associated with more frequent 
complications, nor decreased use of chemoradiotherapy. 
Implementation of NICE TA121 Guidance is extremely variable 
in diff erent MDTs across the United Kingdom. 
 Keywords:  Brain neoplasms; implementing NICE guidance; 
carmustine wafers; improving outcomes guidance 
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biodegradable polymers that release 7.7 mg of carmustine 
over a few weeks directly into the resection cavity. A phase 
III study in newly diagnosed high grade gliomas showed 
that carmustine wafers were well tolerated and associated 
with a survival advantage. 6 NICE issued guidance on the use 
of carmustine wafers for the treatment of newly diagnosed 
gliomas in June 2007 (NICE Technology Appraisal Guidance 
TA121). 7 Th e guidance recommended the use of carmustine 
wafers as an option for the treatment of newly diagnosed 
high grade gliomas (WHO Grade III and IV) in patients where 
it is felt that 90% of the tumour could be resected, and who 
are treated in specialist centres that conform to guidance in 
 ‘ Improving outcomes for people with brain and other central 
nervous system tumours ’. 8 Multidisciplinary teams should 
be used to enable preoperative identifi cation of patients in 
whom maximal resection is likely to be achieved. 
 Th e primary aim of this study is to assess the variation of 
implementation of the NICE technology appraisal concerning 
carmustine wafers by MDTs throughout the United Kingdom 
and explore the reasons for not using this treatment option. 
Secondary aims were to evaluate morbidity associated with 
carmustine wafer insertion and whether patients having this 
treatment were denied access to other oncological therapies 
for their brain tumour. 
 Methods 
 All centres who conform to the guidance  ‘ Improving Out-
comes for people with brain and other central nervous system 
tumours ’ across the United Kingdom were approached by letter 
to participate in the study. REC approval (South West Research 
Ethics Committee 08/H0206/35) was sought and local Trust 
R&D approval was obtained in all participating centres. 
 MDT teams identifi ed eligible patients who met the inclu-
sion criteria during routine MDT meetings. Eligible patients 
included those aged    18 years at the time of diagnosis with 
a radiological diagnosis of probable high grade glioma (WHO 
grade III or IV) where a maximal resection (90% or more) was 
judged likely to be possible. Data was recorded prospectively 
by the nominated study researcher in each centre (Neurosur-
geon, Neuro-oncologist or Neuro-oncology specialist nurse) 
for patients who received surgery between February 2008 and 
October 2010. Data collected was anonymised-coded for each 
patient, by the assignment of a unique patient identifi cation 
number to each record. Data was recorded post-operatively 
on the details of the surgical procedure and then at 48 hours 
post-surgery. All tissue was categorised according to the WHO 
system by a local Consultant Neuropathologist. Th ere was no 
central pathology review. Th e patient was followed up at 6 
weeks post-radiotherapy by the researcher. Anonymised data 
was transferred to the dedicated study database. Analysis was 
undertaken in MS Excel and SPSS for Windows. 
 Results 
 Centres contributing to study 
 Seventeen of the 31 (55%) neurosurgical centres in Great 
Britain screened 307 patients. Th e catchment areas of these 
units cover a total population of approximately 32 million 
people. Of the 307 patients screened, 11 were deemed ineli-
gible since 8 underwent surgery prior to the study period, 
2 were not newly diagnosed patients, and 1 patient refused 
surgery. Th e centres recruiting patients are listed at the end 
of the paper. Four centres contributed 64% of the sample and 
62% of the carmustine patients. 
 Recruited cohort 
 Th ere were 197 males (67%) and 99 females (33%) with 
a median age of 61 years (interquartile range 53 – 66). All 
patients were over the age of 18, and all were diagnosed with 
high grade gliomas: 260 (88%) with glioblastomas, 7 (2%) 
with gliosarcomas and 27 (9%) with WHO Grade III tumours. 
A histological diagnosis was not available in 2 cases. 94% of 
the total number of tumours were in the supratentorial com-
partment and 169 (57%) in the right hemisphere with 93% 
having a single focus and 20 (7%) crossing the midline. 
 Th e Karnofsky Performance Status (KPS) was recorded in 
289 patients and the median of the sample was 90. Ninety-
one percent of the sample had a KPS of    70, 78%   80 and 
56%    90. Th e WHO performance status (recorded in 289 
patients) was 0 in 111 patients (38%), 1 in 127 (44%), 2 in 38 
(13%), 3 in 7 (2%) and 4 in 6 (2%) patients. 
 A total of 285 patients (96%) had a pre-operative assess-
ment that    90% of the tumour could be resected. In the 
remaining cases, fi ve needed urgent surgery, and in six cases, 
the data was not recorded. Th is decision was made on the 
basis of pre-operative MRI in 86% of cases. 
 Use of carmustine wafers 
 Although 285 patients were felt suitable for maximal resec-
tion (i.e.    90%), only 94 patients (33%) received carmustine 
wafers. In this group of patients, the median age was 61 
(interquartile range 54 – 64), 62% were male, 77 patients (82%) 
had a KPS    80 and 74 (79%) had a WHO score of 0 or 1. Th e 
median number of wafers used was 8 (range 3 – 8). For the 
group treated with carmustine wafers, 95% were glioblasto-
mas or gliosarcomas compared to 88% of those not receiving 
carmustine. Only 3 of the 27 patients with an eligible WHO III 
tumour had carmustine wafers inserted. 
 Of the 191 patients suitable for maximal resection who did 
not receive carmustine wafers, 74 (39%) had intra-operative 
reasons why carmustine was not used, including 32 patients 
(17%) with large exposure of the CSF-ventricles caused by 
tumour resection, 30 patients (16%) where an intra-operative 
decision that maximal resection was not possible, 14 patients 
(7%) where there was no intra-operative cytological diagno-
sis to confi rm high grade glioma and 3 cases (2%) where car-
mustine was not available from pharmacy. Th e other reasons 
for not using carmustine include the surgeon ’ s preference 
in 77 cases (40%), no MDT decision in 34 patients (18%) or 
funding issues in 7 cases (3%). A number of patients had 
multiple reasons for non-insertion of carmustine wafers. Six 
of the neurosurgical centres (35%) did not use carmustine 
wafers at all over the period of this study. 
 Assessment of resection 
 Th e extent of resection was objectively assessed intra-
operatively using 5-aminolevulinc acid fl uorescence surgery 
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in 47 patients (16%), with 3D ultrasound guidance being 
used in another 3 (1%). Intra-operative MRI was not available 
at any of the centres involved in this study. Post-operative 
imaging (CT or MRI) was used to confi rm maximal resec-
tion (i.e.    90%) in 63% of all patients, and 75% of patients 
receiving carmustine. 
 Post-operative status at 48 hours 
 Th ere was no change in either the KPS (77% with KPS    80 
vs. 78% pre-operatively) or WHO status (WHO    1 in 82% vs. 
82% pre-operatively) at 48 hours. Of the 296 patients, 90% 
had no complications, and of the 29 with complications, 3 
had more than one. Seven had a hemiparesis and/or aphasia, 
four had intracerebral haematomas, three had CSF leakage 
from the wound, two cerebral infarcts, two suspected wound 
infections, one seizure, one steroid induced mania and 
the remainder various systemic problems (e.g. pulmonary 
problems, diffi  cult diabetic control and pyrexia). Th ere was 
no diff erence in the incidence of early post-operative com-
plications in those receiving and not receiving carmustine 
( p    0.84) (Table I). Nine complications were reported in the 
carmustine group. In eight cases, they were felt not related 
to the use of carmustine; in the ninth case, causality was not 
recorded. 
 Th e overall median length of stay was 4 days (interquartile 
range 3 – 7). Th ere was no signifi cant diff erence between those 
treated with carmustine wafers (median 4, interquartile range 
2 – 6) and those not treated with carmustine wafers (median 
5, interquartile range 3 – 8). Overall 28 patients (9%) were 
readmitted for a median of 11 days (range 5 – 21). Th ere were 
no statistically signifi cant diff erences between readmission 
for the group treated with carmustine (13% readmitted, 95% 
CI 6.0 – 19.5%; median duration 16 days, range 6 – 20.5) and 
those that did not receive carmustine (8% readmitted, 95% 
CI 4.2 – 11.6%; median duration 10.5 days, range 4.5 – 23.5). 
 Adjuvant therapy 
 Follow-up data was recorded in 288 of all patients (97%) and 
90 of the carmustine patients (96%). In total, 273 of all patients 
(95%) and 86 of the carmustine patients (96%) received 
radiotherapy following surgery. Th e median dose received 
was 60 Gy (range 15 – 60) given in a median of 30 fractions 
(range 2 – 31). Th e median interval between surgery and start-
ing radiotherapy was 40 days (range 3 – 164 days). Th ere was 
no diff erence between carmustine patients (median delay 
41 days; range 14 – 152 days) and non-carmustine patients 
(median delay 40 days; range 3 – 164 days). 
 A total of 181 patients (63%) were prescribed concurrent 
temozolomide with their radiotherapy (Stupp protocol). 9 
Of these, 59 (63% of those receiving carmustine) had also 
been treated with carmustine. A number of 152 patients 
(84%) were prescribed adjuvant temozolomide and 50 had 
received carmustine wafers (i.e. 53% of the patients treated 
with carmustine wafers). 
 Clinical status at 6 weeks following radiotherapy 
 By 6 weeks following radiotherapy, 67% of patients had 
a KPS    80 (compared to 77% at 48 hours and 78% pre-
operatively), and 76% had a WHO    1 (compared to 82% 
pre-operatively and at 48 hours). 
 Review of surgical complications, summarised in Table 
II, at this time revealed that 262 patients had no surgical 
complication. Twenty-six patients (9%) had complications 
and seven of these had more than one. Th ese included brain 
swelling (9), discharge from the wound (5), wound/brain 
infection (7), DVT/PE (5), focal defi cits (2), seizures (2) and 
three deaths. Th ose patients having carmustine wafers did 
not have an increased risk of surgical complications com-
pared to those patients not given carmustine ( p    0.47, Fisher 
exact test). Th ere was no increased complication risk in those 
patients treated with carmustine wafers and temozolomide 
compared to all other patients ( p    1.0, Fisher exact test). 
 Comparing the group receiving chemoradiotherapy and 
carmustine wafers with those treated with chemoradio-
therapy alone, there was no statistically signifi cant increase 
( p    0.16) in complications at 6 weeks post radiotherapy 
(4/122 for temozolomide alone versus 5/59 for temozolo-
mide and carmustine wafers). Both groups had one wound 
leakage each. 
 Discussion 
 In this study, we have shown that although 285 of the cohort 
fi tted the NICE criteria as being suitable for insertion of car-
mustine wafers (patient    18 years, histologically confi rmed 
high grade glioma and pre-operative assessment that    90% 
resection was possible), only 94 patients (33%) received it. 
For the 191 patients not receiving carmustine wafers, there 
were good intra-operative reasons in 79 of patients (41%) 
why they should not be used. In the remaining 58% of cases, 
the reason for not using carmustine was either due to sur-
geon ’ s preference or the lack of an MDT decision. No patient 
received carmustine wafers outside of the NICE criteria. Th is 
suggests compliance with NICE Guidance TA121 was good in 
relation to the management of patients receiving Gliadel, that 
is, selection of patients, but compliance across the United 
Kingdom was variable in terms of allowing patients access to 
the choice of treatments aff orded by the NICE Guidance. 
 Th e aim of the MDT process was to ensure best practice in 
the management of cancers. As a result, the implementation 
 Table II. Complications at 6 weeks post radiotherapy. 
All patients 
( n    288)
Carmustine 
wafers ( n    90)
Non-carmustine 
group ( n    198)
Any complication 26 (9%) 13 (14%) 13 (7%)
Brain swelling 9 (3%) 7 (8%) 2 (1%)
Pseudoabscess 0 (0%) 0 (0%) 0 (0%)
Wound leak 5 (2%) 3 (3%) 2 (1%)
Other complication 21 (7%) 9 (10%) 12 (6%)
    1 complication 7 (2%) 5 (6%) 2 (1%)
 Table I. Complications at 48 hours post-operatively. 
All patients 
( n    296)
Carmustine 
wafers ( n    94)
Non-carmustine 
group ( n    202)
Any complication 29 (10%) 9 (10%) 20 (10%)
Brain swelling 5 (2%) 3 (3%) 2 (1% )
Pseudoabscess 0 (0%) 0 (0%) 0 (0%)
Wound leak 3 (1%) 1 (1%) 1 (0.5%)
Other complication 26 (9%) 8 (9%) 18 (9%)
    1 complication 3 (1%) 2 (2%) 1 (0.5%)
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the time of this study and was only used in a small number of 
patients. Th ere was also a lack of post-operative imaging per-
formed, either due to service restrictions or perceived lack 
of necessity even though it has been shown to be the only 
method to objectively assess the extent of resection. 17 
 Although this study provides a snapshot of surgical neuro-
oncology practice in the United Kingdom, the fi ndings have to 
be tempered by the fact that over 60% of patients were recruited 
from four units. Even if we appreciate that only a quarter of 
glioblastoma patients might be eligible for carmustine wafers 
and would fi t within the inclusion criteria of this study, 18 the 
small number of patients recruited from some centres would 
suggest there has been selection bias in these centres. If we 
were to assume an incidence of 4 per 100  000 for high grade 
gliomas, 19 we would expect 1280 patients diagnosed per year 
in the study population. As recruitment was probably only over 
a 2-year period and that only a quarter of patients might be eli-
gible for carmustine wafers, the observed 296 patients is only 
46% of what we would expect. Th is highlights the diffi  culty of 
recording such data in a clinical setting without the assistance 
of research nurses. In the four largest contributing centres, 
however, the observed 188 patients for this population is close 
to the expected value of 214 patients (88% of expected). 
 Conclusions 
 Th is study has shown that there is great variability in the 
implementation of the NICE TA121 Technology Appraisal 
and that only a third of patients that would be suitable actu-
ally received carmustine wafers. Of those not receiving car-
mustine wafers, 60% were due to surgeon ’ s preference and 
lack of MDT decision. Barriers to implementation need to be 
identifi ed. 
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of NICE guidance was one of the MDT ’ s main roles. It is clear 
from our data that this has not been successful for the TA121 
Technology Appraisal. Only one third of the units contribut-
ing to this study treated any patients with carmustine wafers. 
Th e underlying reasons for this variation remain unclear. 
Although we have information about a pre-operative deci-
sion to treat with or without carmustine wafers, we cannot 
be sure it was derived from a discussion in an MDT and, in 
particular, what infl uenced decision making. Since the pub-
lication of the Stupp Trial, 9 this therapy has been regarded 
as the  ‘ new standard in care ’. 10 Th e role of carmustine wafers 
in primary treatment of malignant gliomas has subsequently 
been neglected because of uncertainties about the potential 
toxicity of a carmustine wafer   temozolomide-radiotherapy 
schedule as well as doubts about the statistical validity of the 
Phase III randomized controlled trial of Gliadel for primary 
malignant glioma. 11 Th e latter doubt has been addressed by 
a recent Cochrane review that shows carmustine wafers do 
increase survival. 12 
 Th ere has been some confusion with NICE combining 
the appraisal of temozolomide and carmustine wafers. Some 
have concluded that the appraisal says these patients can 
be treated with temozolomide OR carmustine wafers. Th is 
is not the case. Both products were approved by NICE, and 
the appraisal states that  ‘ guidance does not relate to the 
sequential use of these treatments ’. No Phase III trials exist 
but a range of recent studies that describe use of carmus-
tine wafers followed by temozolomide-radiotherapy have 
addressed the problem of toxicity. 10,13 – 15 Th e problem of 
combined therapeutic toxicity has also been addressed in an 
eclectic way. In some of these studies toxicity was greater but 
in others the combined treatment made no diff erence. Th ere 
was also variability in median survival times between stud-
ies. Patient cohorts ranged from 28 to 44 patients. A Phase II 
safety study (GALA-5) Trial, ISRCTN 77105850) is underway 
to address this question. In our study, the use of carmustine 
wafers did not aff ect access to adjuvant oncological therapies 
and a particularly encouraging fi nding was that combining 
carmustine wafers with concomitant temozolomide and 
radiotherapy did not increase morbidity compared to resec-
tion and chemoradiotherapy alone. 
 Our data shows that there is no increase in complications 
at either 48 hours post-surgery or 6 weeks post-radiotherapy 
with carmustine wafers. We found similar postsurgical com-
plication rates to those published by Westphal 6 with 3% of 
patients developing wound leakage (compared to 5%) and 
7% developing brain swelling (compared to 9.1%  – although 
in the Westphal study, this was a late event occurring more 
than 6 months in 9 of 11 cases). Th ere was also no increase 
in length of stay or readmission rate, and no increase in com-
plications at 6 weeks post chemoradiotherapy if carmustine 
wafers were inserted. 
 Our study does highlight the lack of adjuvant technolo-
gies to assist resection of these tumours. Although image-
guidance is commonplace in the United Kingdom, intra-
operative ultrasound was used in only a small number of 
cases. 5-ALA, a technique shown in a multicentre Phase III 
trial to improve the extent of resection and thus prolong the 
time to progression 16 was available in only three centres at 
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